These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10172057)

  • 1. Pharmacoeconomics of genetically engineered drugs.
    Jones-Grizzle AJ; Bootman JL
    Pharmacoeconomics; 1992 Jan; 1(1):45-53. PubMed ID: 10172057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of pharmacoeconomics in prescribing research. Part 1: costs--moving beyond the acquisition price for drugs.
    Robertson J; Lang D; Hill S
    J Clin Pharm Ther; 2003 Feb; 28(1):73-9. PubMed ID: 12605622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
    Whittington R; Barradell LB; Benfield P
    Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving therapeutic targets in renal anaemia: considering cost-efficacy.
    Deray G
    Curr Med Res Opin; 2004 Jul; 20(7):1095-101. PubMed ID: 15265254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacoeconomics--an aid to better decision-making.
    Arenas-Guzman R; Tosti A; Hay R; Haneke E;
    J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():34-9. PubMed ID: 16120204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for performing a pharmacoeconomic analysis.
    Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
    Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation.
    Young M; Plosker GL
    Pharmacoeconomics; 2002; 20(10):675-713. PubMed ID: 12162756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of therapeutic drug monitoring in pharmacoeconomics.
    Destache CJ
    Ther Drug Monit; 1993 Dec; 15(6):608-10. PubMed ID: 8122303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current framework of biotechnology products according to the available pharmacoeconomic studies].
    Clemente Bautista S; Mendante Barrenechea L; Montoro Ronsano JB
    Med Clin (Barc); 2003 Apr; 120(13):498-504. PubMed ID: 12716544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.
    Quinn TJ; Dawson J
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):513-22. PubMed ID: 19941428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacoeconomics of high-cost biotechnology products.
    Dana WJ; Farthing K
    Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment.
    Choy CK; Spencer AP; Nappi JM
    Pharmacotherapy; 2007 May; 27(5):707-14. PubMed ID: 17461706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of antibacterial treatment.
    Davey PG; Malek MM; Parker SE
    Pharmacoeconomics; 1992 Jun; 1(6):409-37. PubMed ID: 10147022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the pharmacoeconomics of pharmacogenetics.
    Dervieux T; Bala MV
    Pharmacogenomics; 2006 Dec; 7(8):1175-84. PubMed ID: 17184205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting.
    Reichardt B
    J Clin Pharm Ther; 2006 Oct; 31(5):503-12. PubMed ID: 16958829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.